Structure-Based Analysis of Five Novel Disease-Causing Mutations in 21-Hydroxylase-Deficient Patients
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is the most frequent inborn error of metabolism, and accounts for 90-95% of CAH cases. The affected enzyme, P450C21, is encoded by the CYP21A2 gene, located together with a 98% nucleotide sequence identity CYP21A1P pseudogene, on chromosome 6p21.3. Even though most patients carry CYP21A1P-derived mutations, an increasing number of novel and rare mutations in disease causing alleles were found in the last years. In the present work, we describe five CYP21A2 novel mutations, p.R132C, p.149C, p.M283V, p.E431K and a frameshift g.2511_2512delGG, in four non-classical and one salt wasting patients from Argentina. All novel point mutations are located in CYP21 protein residues that are conserved throughout mammalian species, and none of them were found in control individuals. The putative pathogenic mechanisms of the novel variants were analyzed in silico. A three-dimensional CYP21 structure was generated by homology modeling and the protein design algorithm FoldX was used to calculate changes in stability of CYP21A2 protein. Our analysis revealed changes in protein stability or in the surface charge of the mutant enzymes, which could be related to the clinical manifestation found in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The FoldX web server: an online force field
Schymkowitz, J., Borg, J., Stricher, F., Nys, R., Rousseau, F., & Serrano, L. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki387 · Cited by 2,759
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432 · cited 1×
“The adrenocortical 21-hydroxylase is one of the key enzymes in glucocorticoid and mineralocorticoid biosynthesis. Mutations in the CYP21A2 gene have been reported in individuals affected with CAH due to 21-hydroxylase deficiency. To date, a great number of different mutations in the CYP21A2 gene have been described. M…”
Congenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628
Structure of human steroid 21-hydroxylase genes.
White, P. C., New, M. I., & Dupont, B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.14.5111 · Cited by 569
High frequency of nonclassical steroid 21-hydroxylase deficiency
SPEISER, P. W., DUPONT, B. O., RUBINSTEIN, P., PIAZZA, A., KASTELAN, A., & NEW, M. I. (1986) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198604000-00017 · Cited by 523
Krone, N., Braun, A., Roscher, A. A., Knorr, D., & Schwarz, H. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6441 · Cited by 397
Tusie-Luna, M. T., Traktman, P., & White, P. C. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)45304-x · Cited by 254 · cited 2×
“V281L mutation, for example, for which although both models predicted a stabilizing energy, previous in vitro analyses had demonstrated a decreased enzymatic activity [23,24].”
Newborn screening for congenital adrenal hyperplasia
Therrell, B. L. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(08)70017-3 · Cited by 221
Clinical review 54: genetics, diagnosis, and management of 21-hydroxylase deficiency
Miller, W. L. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.2.241 · Cited by 167
Wedell, A., & Luthman, H. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.5.499 · Cited by 160
Wedell, A., Ritzén, E. M., Haglund-Stengler, B., & Luthman, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7232 · Cited by 150
Jääskeläinen, J., Levo, A., Voutilainen, R., & Partanen, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.10.4271 · Cited by 149
Current status of neonatal screening for congenital adrenal hyperplasia
Pang, S., & Shook, M. K. (1997) · Current Opinion in Pediatrics · doi:10.1097/00008480-199708000-00018 · Cited by 104 · cited 1×
“Neonatal screening programs performed since 1977 have shown an overall incidence of 1∶15000 live births for the classical form”
Dolž;an, V, Sólyom, J., Fekete, G., Kovács, J., Rakosnikova, V, Votava, F., Lebl, J., Pribilincova, Z., Baumgartner-Parzer, S., Riedl, S., et al. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01944 · Cited by 96
Exhaustive screening of the 21-hydroxylase gene in a population of hyperandrogenic women
Blanché, H., Vexiau, P., Clauin, S., Le Gall, I., Fiet, J., Mornet, E., Dausset, J., & Bellanné-Chantelott, C. (1997) · Human Genetics · doi:10.1007/s004390050586 · Cited by 85
Wu, D. A., & Chung, B. C. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115334 · Cited by 80 · cited 2×
“V281L mutation, for example, for which although both models predicted a stabilizing energy, previous in vitro analyses had demonstrated a decreased enzymatic activity [23,24].”
Tardy, V., Menassa, R., Sulmont, V., Lienhardt-Roussie, A., Lecointre, C., Brauner, R., David, M., & Morel, Y. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1202 · Cited by 73
Loidi, L., Quinteiro, C., Parajes, S., Barreiro, J., Lestón, D. G., Cabezas‐Agrícola, J. M., Sueiro, A. M., Araujo‐Vilar, D., Catro‐Feijóo, L., Costas, J., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02465.x · Cited by 55
Wijesuriya, S. D., Zhang, G., Dardis, A., & Miller, W. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.53.38097 · Cited by 54 · cited 1×
“No variations were either found when we analyzed, by direct sequencing, two previously described regulatory regions [25,26] (data not shown).”
The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency
Gomes, L. G., Huang, N., Agrawal, V., Mendonça, B. B., Bachega, T. A. S. S., & Miller, W. L. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0304 · Cited by 52
Ezquieta, B., Cueva, E., Varela, J., Oliver, A., Fernández, J., & Jariego, C. (2002) · Acta Paediatrica · doi:10.1080/080352502760148595 · Cited by 47 · cited 1×
“Interestingly, another point mutation at the same position, 283L, has previously been associated with the NC form of the disease [31].”
Bleicken, C., Loidi, L., Dhir, V., Parajes, S., Quinteiro, C., Dominguez, F., Grötzinger, J., Sippell, W. G., Riepe, F. G., Arlt, W., et al. (2009) · Human Mutation · doi:10.1002/humu.20926 · Cited by 15
Cited by
Structure-phenotype correlations of human CYP21A2 mutations in congenital adrenal hyperplasia
Haider, S., Islam, B., D’Atri, V., Sgobba, M., Poojari, C., Sun, L., Yuen, T., Zaidi, M., & New, M. I. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221133110 · Cited by 127
CYP21A2 mutation update: Comprehensive analysis of databases and published genetic variants
Simonetti, L., Bruque, C. D., Fernández, C. S., Benavides-Mori, B., Delea, M., Kolomenski, J. E., Espeche, L. D., Buzzalino, N. D., Nadra, A. D., & Dain, L. (2018) · Human Mutation · doi:10.1002/humu.23351 · Cited by 122
Self-citationBaumgartner-Parzer, S., Witsch-Baumgartner, M., & Hoeppner, W. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-0653-5 · Cited by 110
Concolino, P., & Costella, A. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0319-y · Cited by 96
Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia
Sarafoglou, K., Banks, K., Gaviglio, A., Hietala, A., McCann, M., & Thomas, W. (2012) · PEDIATRICS · doi:10.1542/peds.2012-1219 · Cited by 69
Metadata
- Authors
- Minutolo, C., Nadra, A. D., Fernández, C., Taboas, M., Buzzalino, N., Casali, B., Belli, S., Charreau, E. H., Alba, L., & Dain, L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-01-11
- Volume
- 6
- Issue
- 1
- Pages
- e15899
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2014677840
- Cited by
- 31
- References
- 22
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.